In this Issue:
VeriStrat validated in NSCLC
Erlotinib vs docetaxel in an EGFR-unselected cohort
Should EGFR TKIs be used in EGFR wt patients?
Serum oestrogens and lung cancer survival
Target aromatase expression in lung adenocarcinoma?
PD-L1 expression: a prognostic and predictive biomarker?
Racotumomab immunisation in advanced NSCLC
Adding figitumumab to chemotherapy stopped forfutility
EGFR gene mutation testing: the Australian experience
Targeted next-generation sequencing improves efficacy of EGFR TKIs?
Please login below to download this issue (PDF)